Mass spectrometry-based metabolomics for irritable bowel syndrome biomarkers

BACKGROUND

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder without obvious structural abnormalities or consistent associated biomarkers, making its diagnosis difficult. In the present study, we used a urine-based metabolomics approach to identify IBS biomarkers.

METHODS

We used an ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS) on urine samples from patients suffering from IBS and healthy controls. Data were coupled for multivariate statistical analysis methods.

RESULTS

We selected 30 differential metabolites associated with IBS and found steroid hormone biosynthesis and histidine metabolism alterations in patients with IBS that may be involved in the pathogenesis of the disease. In addition, we identified a panel of five metabolite markers composed of cortisone, citric acid, tiglylcarnitine, N6,-N6,-N6-trimethyl-L-lysine and L-histidine that could be used to discriminate between patients and healthy controls and may be appropriate as IBS diagnosis biomarkers.

CONCLUSION

Our findings indicate that metabolomics combined with pattern recognition can be useful to identify disease diagnostic IBS markers.

CLINICAL TRIAL REGISTRATION

ChiCTR1800020072.

Molecularly imprinted cryogel cartridges for the specific filtration and rapid separation of interferon alpha

Molecularly imprinted cryogel-based specific filtration cartridges for highly selective, repeatable and fast interferon α-2b separation even if under competitive conditions.